vs
Side-by-side financial comparison of AMREP CORP. (AXR) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $14.6M, roughly 1.3× AMREP CORP.). AMREP CORP. runs the higher net margin — 21.6% vs -0.8%, a 22.4% gap on every dollar of revenue. On growth, AMREP CORP. posted the faster year-over-year revenue change (93.8% vs -25.7%). AMREP CORP. produced more free cash flow last quarter ($5.4M vs $-15.8M). Over the past eight quarters, AMREP CORP.'s revenue compounded faster (-13.6% CAGR vs -15.9%).
AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
AXR vs CTMX — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.6M | $18.7M |
| Net Profit | $3.1M | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | 20.6% | -6.9% |
| Net Margin | 21.6% | -0.8% |
| Revenue YoY | 93.8% | -25.7% |
| Net Profit YoY | 338.9% | 97.6% |
| EPS (diluted) | $0.58 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $14.6M | — | ||
| Q4 25 | $9.4M | — | ||
| Q3 25 | $17.9M | — | ||
| Q2 25 | $11.2M | $18.7M | ||
| Q1 25 | $7.5M | $50.9M | ||
| Q4 24 | $11.9M | $38.1M | ||
| Q3 24 | $19.1M | $33.4M | ||
| Q2 24 | $19.5M | $25.1M |
| Q1 26 | $3.1M | — | ||
| Q4 25 | $1.2M | — | ||
| Q3 25 | $4.7M | — | ||
| Q2 25 | $3.9M | $-154.0K | ||
| Q1 25 | $717.0K | $23.5M | ||
| Q4 24 | $4.0M | $18.9M | ||
| Q3 24 | $4.1M | $5.7M | ||
| Q2 24 | $4.1M | $-6.5M |
| Q1 26 | 20.6% | — | ||
| Q4 25 | 11.9% | — | ||
| Q3 25 | 34.4% | — | ||
| Q2 25 | 31.7% | -6.9% | ||
| Q1 25 | 5.7% | 44.4% | ||
| Q4 24 | 26.4% | 46.4% | ||
| Q3 24 | 26.1% | 12.3% | ||
| Q2 24 | 23.9% | -33.7% |
| Q1 26 | 21.6% | — | ||
| Q4 25 | 12.8% | — | ||
| Q3 25 | 26.3% | — | ||
| Q2 25 | 34.8% | -0.8% | ||
| Q1 25 | 9.5% | 46.2% | ||
| Q4 24 | 33.9% | 49.6% | ||
| Q3 24 | 21.3% | 17.2% | ||
| Q2 24 | 21.2% | -26.0% |
| Q1 26 | $0.58 | — | ||
| Q4 25 | $0.22 | — | ||
| Q3 25 | $0.87 | — | ||
| Q2 25 | $0.73 | — | ||
| Q1 25 | $0.13 | — | ||
| Q4 24 | $0.75 | — | ||
| Q3 24 | $0.76 | — | ||
| Q2 24 | $0.77 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $50.0M | $49.0M |
| Total DebtLower is stronger | $21.0K | — |
| Stockholders' EquityBook value | $139.4M | $119.9M |
| Total Assets | $143.9M | $175.1M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $50.0M | — | ||
| Q4 25 | $44.6M | — | ||
| Q3 25 | $48.9M | — | ||
| Q2 25 | $39.5M | $49.0M | ||
| Q1 25 | $36.9M | $47.6M | ||
| Q4 24 | $40.1M | $38.1M | ||
| Q3 24 | $40.4M | $40.6M | ||
| Q2 24 | $29.7M | $43.2M |
| Q1 26 | $21.0K | — | ||
| Q4 25 | $23.0K | — | ||
| Q3 25 | $25.0K | — | ||
| Q2 25 | $26.0K | — | ||
| Q1 25 | $29.0K | — | ||
| Q4 24 | $32.0K | — | ||
| Q3 24 | $34.0K | — | ||
| Q2 24 | $35.0K | — |
| Q1 26 | $139.4M | — | ||
| Q4 25 | $136.0M | — | ||
| Q3 25 | $134.7M | — | ||
| Q2 25 | $130.0M | $119.9M | ||
| Q1 25 | $126.0M | $25.0M | ||
| Q4 24 | $125.1M | $-456.0K | ||
| Q3 24 | $122.2M | $-23.5M | ||
| Q2 24 | $118.0M | $-31.2M |
| Q1 26 | $143.9M | — | ||
| Q4 25 | $140.1M | — | ||
| Q3 25 | $140.7M | — | ||
| Q2 25 | $133.8M | $175.1M | ||
| Q1 25 | $128.9M | $98.5M | ||
| Q4 24 | $129.1M | $120.5M | ||
| Q3 24 | $127.0M | $139.0M | ||
| Q2 24 | $122.8M | $159.2M |
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.4M | $-15.8M |
| Free Cash FlowOCF − Capex | $5.4M | $-15.8M |
| FCF MarginFCF / Revenue | 37.0% | -84.6% |
| Capex IntensityCapex / Revenue | 0.1% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $20.2M | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | — | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $10.2M | $-15.8M | ||
| Q1 25 | $-3.2M | $-21.0M | ||
| Q4 24 | $-182.0K | $-19.9M | ||
| Q3 24 | $10.7M | $-20.7M | ||
| Q2 24 | $10.7M | $-19.5M |
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | — | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $9.7M | $-15.8M | ||
| Q1 25 | $-3.3M | $-21.2M | ||
| Q4 24 | $-268.0K | $-20.0M | ||
| Q3 24 | $10.7M | $-20.7M | ||
| Q2 24 | $10.3M | $-19.6M |
| Q1 26 | 37.0% | — | ||
| Q4 25 | -45.9% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 86.4% | -84.6% | ||
| Q1 25 | -43.4% | -41.6% | ||
| Q4 24 | -2.3% | -52.5% | ||
| Q3 24 | 55.8% | -62.1% | ||
| Q2 24 | 52.5% | -78.2% |
| Q1 26 | 0.1% | — | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 5.2% | 0.1% | ||
| Q1 25 | 0.3% | 0.2% | ||
| Q4 24 | 0.7% | 0.2% | ||
| Q3 24 | 0.2% | 0.1% | ||
| Q2 24 | 2.3% | 0.4% |
| Q1 26 | 1.72× | — | ||
| Q4 25 | -3.54× | — | ||
| Q3 25 | 2.03× | — | ||
| Q2 25 | 2.63× | — | ||
| Q1 25 | -4.51× | -0.89× | ||
| Q4 24 | -0.05× | -1.05× | ||
| Q3 24 | 2.63× | -3.61× | ||
| Q2 24 | 2.59× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXR
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
